In this online CME self-learning program:
Psoriasis, characterized by chronic inflammation of the skin and hyperproliferation and abnormal differentiation of the stratified epidermis, is one of the most common autoimmune disease in the U.S. It presents clinically as red, scaly plaques on the skin and ranges in severity from minor, localized lesions to complete body coverage. It is also associated with inflammation of the joints and enthesial attachments and has potential of articular destruction, a complication known as psoriatic arthritis that affects up to 30-40% of those with the disease. Treatment for psoriasis include biological agents, phototherapy, traditional systemic drugs, topical steroids and topical non-steroids.
Identifying the severity of psoriasis remains key in choosing the right medication; doing so is still predominantly based on the rule of nine in determining the percentage of body surface area affected. Literature suggests that correct evaluation of lesion sizes, a precise calculation of the treatments quantity to be prescribed, clear instructions, and treatment-specific individual dosing devices may help achieve higher rates of adherence and treatment success.
Epidemiology and risk factors for psoriasis
Review and updates in symptomology and diagnostic considerations
Treatment options in patients with psoriasis
Barrier to optimal care in patients with psoriasis
Healthcare professionals specializing in: allergy, dermatology, immunology, internal and family medicine, and those who otherwise may treat patients with psoriasis.
This program is supported by an educational grant from AMGEN.
Release Date: June 30, 2014 -- Expiration Date: June 30, 2016
Faculty: Jennifer Soung, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Jennifer Soung, MD has is a consultant or has received Research and Educational Grants from Amgen, Pfizer, Janssen, Celgene, and Abbvie
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.